A detailed history of Burney CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Burney CO holds 46,161 shares of VRTX stock, worth $20.8 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares
46,161
Previous 38,829 18.88%
Holding current value
$20.8 Million
Previous $18.2 Million 17.96%
% of portfolio
0.84%
Previous 0.77%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$460.0 - $505.78 $3.37 Million - $3.71 Million
7,332 Added 18.88%
46,161 $21.5 Million
Q2 2024

Jul 29, 2024

BUY
$392.81 - $485.53 $14.9 Million - $18.4 Million
37,997 Added 4566.95%
38,829 $18.2 Million
Q1 2024

May 22, 2024

SELL
$407.69 - $446.08 $2.31 Million - $2.53 Million
-5,666 Reduced 87.2%
832 $347,000
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $1.99 Million - $2.39 Million
5,815 Added 851.39%
6,498 $2.64 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $19,614 - $21,022
58 Added 9.28%
683 $237,000
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $196,512 - $219,943
625 New
625 $219,000
Q4 2022

Feb 06, 2023

BUY
$285.76 - $321.48 $84,299 - $94,836
295 Added 5.52%
5,639 $1.63 Million
Q3 2022

Nov 15, 2022

BUY
$273.83 - $305.53 $1.22 Million - $1.36 Million
4,440 Added 491.15%
5,344 $1.55 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $21,851 - $27,207
-93 Reduced 9.33%
904 $255,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $220,755 - $260,187
997 New
997 $260,000
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $391,888 - $456,799
-1,893 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$207.01 - $276.09 $27,532 - $36,719
-133 Reduced 6.56%
1,893 $447,000
Q3 2020

Dec 14, 2020

BUY
$255.65 - $303.1 $517,946 - $614,080
2,026 New
2,026 $551,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Burney CO Portfolio

Follow Burney CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burney CO, based on Form 13F filings with the SEC.

News

Stay updated on Burney CO with notifications on news.